Treatment of peripheral t cell lymphoma
AssigneeInnate Pharma
InventorsCÉCILE BONNAFOUS, HÉLÈNE SICARD, RENAUD BUFFET, MATHIEU BLERY
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods for the treatment, prevention and diagnosis of peripheral T-cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express NKp46 at their surface, and pharmaceutical compositions comprising the same. The disclosure also relates to the use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T-cell lymphoma.
Claims16
A method for treating a peripheral T cell lymphoma (PTCL) in an individual, the method comprising administering to an individual a therapeutically active amount of a compound that binds an NKp46 polypeptide and depletes NKp46-expressing tumor cells.
A method for detecting in an individual a peripheral T cell lymphoma (PTCL) selected from the group consisting of NK/T-lymphoma, enteropathy associated T cell lymphoma (EATL) and refractory celiac disease (RCD) susceptible to progressing to EATL, the method comprising detecting an NKp46 nucleic acid or polypeptide in a biological sample from an individual.
Dependencies are inferred from the claim text.